Table 1.
Characteristics of 274 adult AML patients, by R132 mutation status.
| R132 Mutation (N =12) | R132 Wildtype (N = 262) | |||||
|---|---|---|---|---|---|---|
| Patients | % | Patients | % | P a | ||
| Gender | Female | 4 | 33% | 122 | 47% | 0.56 |
| Male | 8 | 67% | 140 | 53% | ||
| Race | Asian | 1 | 8% | 6 | 2% | 0.34 |
| Black | 0 | 0% | 26 | 10% | ||
| Native American/ Alaskan | 0 | 0% | 1 | 0.4% | ||
| White | 11 | 92% | 226 | 86% | ||
| Unknown | 0 | 0% | 3 | 1% | ||
| Karyotype (10 R132+, 193 WT) b | Normal | 6 | 60% | 79 | 41% | 0.33 |
| +8 | 1 | 10% | 27 | 14% | 1.00 | |
| -7/del(7q) | 0 | 0% | 16 | 8% | 1.00 | |
| CBF abnormality | 0 | 0% | 22 | 11% | 0.61 | |
| Abn(11q23) | 0 | 0% | 9 | 5% | 1.00 | |
| Other clonal abnormalities | 2 | 20% | 44 | 23% | 1.00 | |
| Nonclonal abnormality | 1 | 10% | 6 | 3% | 0.30 | |
| FLT3/ITD (12 R132+, 243 WT) | Present | 6 | 50% | 83 | 34% | 0.35 |
| Absent | 6 | 50% | 160 | 66% | ||
| Median | Min-Max | Median | Min-Max | P a | ||
| Age (yrs) | 61 | 34-81 | 63 | 18-88 | 0.59 | |
| BM Blasts (%; 11 R132+, 246 WT) | 80% | 38-99% | 71% | 0-99% | 0.59 | |
| WBC (×109/L) | 59.2 | 1.2-98.2 | 29.1 | 0.7-298.0 | 0.19 | |
| Circ. Blasts (%; 10 R132+, 255 WT) | 48% | 4-99% | 42% | 0-99% | 0.52 | |
| Platelets (×109/L; 11 R132+, 262 WT) | 53 | 10-189 | 57 | 2-1052 | 0.98 | |
| Hemoglobin (g/dL; 12 R132+, 256 WT) | 9.5 | 6.0-12.2 | 9.2 | 4.3-14.3 | 0.67 | |
| Estimate | 95% CI | Estimate | 95% CI | P a | ||
| Response to induction chemotherapy (%) | Complete response | 75% | 43-95% | 51% | 45-57% | 0.14 |
| Resistant disease | 17% | 2-48% | 29% | 24-35% | 0.52 | |
| Other, not evaluable | 8% | --- | 20% | --- | ||
| Overall survival at 5 years (%) | 25% | 5-57% | 17% | 12-21% | 0.55 | |
| Relapse-free survival at 5 years (%) | 33% | 7-70% | 22% | 14-29% | 0.51 | |
a
P-values based on Fisher’s exact test (sex, karyotypes, FLT3/ITD, response); Pearson chi-squared test (race; exact calculation); Wilcoxon rank-sum test (continuous variables); or logrank test (overall and relapse-free survival). Results based on all 274 patients except where indicated.
b
Total of karyotype categories in R132 Wildtype column exceeds 193 because some patients have multiple clonal abnormalities.